Trueo announced plans to migrate its prediction market protocol from the Base Layer 2 to the Ethereum mainnet, citing Ethereum's better liquidity, integration, and long-term infrastructure. Existing Base markets will remain operational until their expiry, but new markets with expirations beyond January 31, 2027, should be created on Ethereum. TRUE token holders will have an open-ended migration window, with future staking rewards moving to Ethereum. Ethereum co-founder Vitalik Buterin praised Trueo's decentralized and ethical approach to prediction markets. The migration is ongoing, with Base contracts still active and no Ethereum deployment addresses yet published.
The Trueo Ethereum migration plan is the subject, with Pluang market data providing context. For readers following major cryptocurrencies on Pluang as of Sep 22, 2026 09:21 WIB, 44 of 50 major cryptocurrencies rose while 5 fell. Among notable movers, FIL rose 7.15% to Rp17.853 with a typical hold time of 99 days, XRP increased 6.94% to Rp26.876 with a shorter hold time of 71 days and a higher buy order activity of 65%, contrasting with AXS which rose 6.87% to Rp19.165 but saw 97% sell orders and a typical hold time of 62 days.
Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...
CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...
At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...
Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...
Johnson & Johnson announced promising Phase 1 results for a novel immunotherapy combining pasritamig and JNJ-9401, targeting two prostate cancer proteins to activate T cells. In the trial, 73% of patients saw PSA levels drop by at least 50%, with nea...
